The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Production of virus-like particles for vaccines
Open accessAbstract
Highlights • Virus-Like Particles (VLPs) present several advantages over conventional vaccines which make them attractive for vaccination.• Interest in VLP design and production has been increasing in recent years.• Mammalian cell production approach can produce more immunogenic VLPs due to the post-translation modifications accessed.• VLP vaccines against several infectious diseases are already on the market, with others in preclinical and clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pushko, P., Pumpens, P., & Grens, E. (2013) · Intervirology · doi:10.1159/000346773 · Cited by 5,950
Production of recombinant protein therapeutics in cultivated mammalian cells
Wurm, F. M. (2004) · Nature Biotechnology · doi:10.1038/nbt1026 · Cited by 2,032
Harper, D. M., Franco, E. L., Wheeler, C., Ferris, D. G., Jenkins, D., Schuind, A., Zahaf, T., Innis, B., Naud, P., De Carvalho, N. S., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17398-4 · Cited by 1,643
Hepatitis B Virus Immunopathogenesis
Chisari, F. V. (1995) · Annual Review of Immunology · doi:10.1146/annurev.immunol.13.1.29 · Cited by 1,609
Nucleotide sequence of the hepatitis B virus genome (subtype ayw) cloned in E. coli
Galibert, F., Mandart, E., Fitoussi, F., Tiollais, P., & Charnay, P. (1979) · Nature · doi:10.1038/281646a0 · Cited by 981
The production of recombinant pharmaceutical proteins in plants
Ma, J. K.-C., Drake, P. M. W., & Christou, P. (2003) · Nature Reviews Genetics · doi:10.1038/nrg1177 · Cited by 960
Virus-like particles in vaccine development
Roldão, A., Mellado, M. C. M., Castilho, L. R., Carrondo, M. J., & Alves, P. M. (2010) · Expert Review of Vaccines · doi:10.1586/erv.10.115 · Cited by 845
HIV-1 assembly, budding, and maturation
Sundquist, W. I., & Krausslich, H.-G. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006924 · Cited by 814
Plotkin, S. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1400472111 · Cited by 642
Mammalian cell protein expression for biopharmaceutical production
Zhu, J. (2012) · Biotechnology Advances · doi:10.1016/j.biotechadv.2011.08.022 · Cited by 491
Cited by
Nooraei, S., Bahrulolum, H., Hoseini, Z. S., Katalani, C., Hajizade, A., Easton, A. J., & Ahmadian, G. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-00806-7 · Cited by 869
Efficacy and safety of COVID-19 vaccines
Graña, C., Ghosn, L., Evrenoglou, T., Jarde, A., Minozzi, S., Bergman, H., Buckley, B. S., Probyn, K., Villanueva, G., Henschke, N., et al. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015477 · Cited by 310
Recent Advances in CRISPR/Cas9 Delivery Strategies
Yip, B. (2020) · Biomolecules · doi:10.3390/biom10060839 · Cited by 292
Delfi, M., Sartorius, R., Ashrafizadeh, M., Sharifi, E., Zhang, Y., De Berardinis, P., Zarrabi, A., Varma, R. S., Tay, F. R., Smith, B. R., et al. (2021) · Nano Today · doi:10.1016/j.nantod.2021.101119 · Cited by 253
Production and characterisation of stabilised PV-3 virus-like particles using Pichia pastoris
Sherry, L., Grehan, K., Swanson, J. J., Bahar, M. W., Porta, C., Fry, E. E., Stuart, D. I., Rowlands, D. J., & Stonehouse, N. J. (2022) · doi:10.1101/2022.09.16.508282 · Cited by 18
Metadata
- Authors
- Fuenmayor, J., Gòdia, F., & Cervera, L.
- Venue
- New Biotechnology
- Publisher
- Elsevier BV
- Published
- 2017-10
- Volume
- 39
- Issue
- Pt B
- Pages
- 174-180
- ISSN
- 1871-6784 (ISSN-L)
- OpenAlex
- W2741681003
- Cited by
- 318
- References
- 52
- FWCI
- 7.18
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Production of virus-like particles for vaccines. https://app.cochat.ai/papers/10.1016/j.nbt.2017.07.010
- The paper
- Fuenmayor, J., Gòdia, F., & Cervera, L. (2017). Production of virus-like particles for vaccines. New Biotechnology. https://doi.org/10.1016/j.nbt.2017.07.010
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.